The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Blinatumomab (Brand name: Blincyto)
- Manufactured by
FDA-approved indication: March 2018 approval for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Previously approved in December 2014 for treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
National Library of Medicine Drug Information PortalMedline Plus Health Information